These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Chan WM; Lai TY; Lai RY; Tang EW; Liu DT; Lam DS Retina; 2008 Jan; 28(1):85-93. PubMed ID: 18185143 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy. Park YJ; Kim YK; Park KH; Woo SJ Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment. Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913 [TBL] [Abstract][Full Text] [Related]
25. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related]
26. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
27. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387 [TBL] [Abstract][Full Text] [Related]
28. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Kim KS; Lee WK; Lee SB Am J Ophthalmol; 2014 Feb; 157(2):366-373.e1. PubMed ID: 24184226 [TBL] [Abstract][Full Text] [Related]
29. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824 [TBL] [Abstract][Full Text] [Related]
30. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Chan WM; Lai TY; Lai RY; Liu DT; Lam DS Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401 [TBL] [Abstract][Full Text] [Related]
31. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Rouvas A; Stavrakas P; Theodossiadis PG; Stamatiou P; Milia M; Giannakaki E; Datseris I Eur J Ophthalmol; 2012; 22(3):417-22. PubMed ID: 21928269 [TBL] [Abstract][Full Text] [Related]
32. Half-time photodynamic therapy for central serous chorioretinopathy. Tsai MJ; Hsieh YT Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838 [TBL] [Abstract][Full Text] [Related]
33. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy. Kim YK; Ryoo NK; Woo SJ; Park KH Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629 [TBL] [Abstract][Full Text] [Related]
34. The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study. Ozkaya A; Alkin Z; Ozveren M; Yazici AT; Taskapili M Eye (Lond); 2016 Jul; 30(7):1005-10. PubMed ID: 27101755 [TBL] [Abstract][Full Text] [Related]
35. Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Atik A; Hu Y; Yu H; Yang C; Cai B; Tao Y; Li D; Chen Y; Lu L; Li G; Yuan L BMC Ophthalmol; 2017 Aug; 17(1):140. PubMed ID: 28797227 [TBL] [Abstract][Full Text] [Related]
37. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF; Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758 [TBL] [Abstract][Full Text] [Related]
38. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398 [TBL] [Abstract][Full Text] [Related]
39. Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study. Gao T; Qu J; Xiao J; Hu J; Zhao M Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1429-1439. PubMed ID: 29869216 [TBL] [Abstract][Full Text] [Related]
40. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study. Haga F; Maruko R; Sato C; Kataoka K; Ito Y; Terasaki H PLoS One; 2017; 12(7):e0181479. PubMed ID: 28742138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]